This therapy involves the administration of LNP-encapsulated mRNA encoding cas9 protein and gRNA targeting misfolded transthyretin (TTR), a protein predominantly accumulated in the heart and nerves of transthyretin amyloidosis patients. Here, TTR is linked to prealbumin measurement.